PATIENTS (PTS) WITH RECURRENT GYNECOLOGIC CANCER WHOSE TUMORS HAVE ACTIVATING WNT PATHWAY MUTATIONS RESPOND BETTER TO DKN-01, A DICKKOPF-1 (DKK1) INHIBITOR

被引：2
|
作者：
Arend, R. [1 ]
Castro, C. [2 ]
Matulonis, U. [3 ]
Hamilton, E. [4 ]
Gunderson, C. [5 ]
LyBarger, K. [6 ]
Goodman, H. [7 ]
Duska, L. [8 ]
Mahdi, H. [9 ]
ElNaggar, A. [10 ]
Kagey, M. [11 ]
Barroilhet, L. [12 ]
Bradley, W. [13 ]
Sachdev, J. [14 ]
O'Malley, D.
Sirard, C. [15 ]
Birrer, M. [16 ]
机构：
[1] Univ Alabama Birmingham, Gynecol Oncol, Birmingham, AL USA
[2] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA
[3] Dana Farber Canc Inst, Gynecol Oncol, Boston, MA 02115 USA
[4] Sarah Cannon Res Inst Tennessee Oncol, Breast & Gynecol Canc Res Program, Nashville, TN USA
[5] Univ Oklahoma, Gynecol Oncol, Hlth Sci Ctr, Oklahoma City, OK USA
[6] Sarah Cannon Res Inst, HCA Midwest, Gynecol Oncol, Kansas City, MO USA
[7] Florida Canc Specialists, Gynecol Oncol, W Palm Beach, FL USA
[8] Univ Virginia Hlth Syst, Gynecol Oncol, Charlottesville, VA USA
[9] Cleveland Clin, Gynecol Oncol, Cleveland, OH 44106 USA
[10] West Canc Clin, Gynecol Oncol, Memphis, TN USA
[11] Leap Therapeut Inc, Res, Cambridge, MA USA
[12] Univ Wisconsin Hosp & Clin, Gynecol Oncol, Madison, WI 53792 USA
[13] Froedtert & Med Coll Wisconsin, Gynecol Oncol, Milwaukee, WI USA
[14] HonorHlth Res Inst, Hematol Oncol, Scottsdale, AZ USA
[15] Ohio State Univ, Gynecol Oncol, Columbus, OH 43210 USA
[16] Leap Therapeut Inc, Clin Res, Cambridge, MA USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2019年 / 29卷
关键词：
D O I：
10.1136/ijgc-2019-IGCS.76
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
76
引用
收藏
页码：A40 / A41
页数：2
相关论文
共 14 条
  • [1] Safety and efficacy of a DKK1 inhibitor (DKN-01) as monotherapy or in combination with paclitaxel in patients with Wnt activated recurrent gynecologic malignancies
    Arend, R. C.
    Castro, C. M.
    Matulonis, U. A.
    Hamilton, E.
    Gunderson, C. C.
    Lybarger, K. S. S.
    Kagey, M.
    Sirard, C.
    Birrer, M. J.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 34 - 34
  • [2] Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies
    Klempner, S. J.
    Bendell, J.
    Villaflor, V. Meucci
    Tenner, L.
    Stein, S.
    Sirard, C. A.
    Newman, W.
    Kagey, M.
    Schlienger, K.
    Strickler, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 222 - 222
  • [3] Potential biomarkers of response to DKK1 blockade with DKN-01 in combination with paclitaxel in advanced esophagogastric cancer (EGC) patients (pts)
    Duda, D. G.
    Sirard, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] TUMORAL DKK1 EXPRESSION CORRELATES WITH BETTER CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED ESOPHAGOGASTRIC CANCER (EGC) TREATED WITH DKN-01
    Klempner, Samuel
    Kagey, Michael
    Sirard, Cynthia
    Sirard, Cynthia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A160 - A160
  • [5] Patients with recurrent gynecologic cancers and Wnt activating mutations demonstrated greater clinical benefit when treated with DKN-01 therapy
    Arend, Rebecca
    Castro, Cesar
    Matulonis, Ursula
    Hamilton, Erika
    Gunderson, Camille
    Lybarger, Kristopher
    Goodman, Howard
    Duska, Linda
    Mahdi, Haider
    ElNaggar, Adam
    Kagey, Michael
    Barroilhet, Lisa
    Bradley, William
    Sachdev, Jasgit
    Sirard, Cynthia
    O'Malley, David
    Birrer, Michael
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S16 - S17
  • [6] Safety and efficacy of Wnt inhibition with a DKK1 inhibitor, DKN-01, in combination with atezolizumab in patients with advanced oesophagogastric adenocarcinoma: Phase IIa results of the WAKING trial
    Turkes, F. S.
    Crux, R.
    Tran, A.
    Cartwright, E.
    Rana, I.
    Johnston, E.
    Dunlop, A.
    Thomas, J.
    Smith, A.
    Smyth, E.
    Fribbens, C.
    Rao, S.
    Watkins, D.
    Chau, I.
    Starling, N.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1120 - S1121
  • [7] Correlation of radiomics of metastatic lesions in gastroesophageal adenocarcinoma (GEA) with tumoral DKK1 mRNA expression and other immune biomarkers in patients (pts) treated with DKN-01
    Sirard, Cynthia A.
    Klempner, Samuel J.
    Naik, Girish S.
    Kagey, Michael
    Nolte, Zak
    Hindosh, Ziad
    Burkett, Andre
    Korn, Ronald Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] Phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients (pts) with DKK1+relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).
    Bendell, Johanna C.
    Murphy, Janet E.
    Mahalingam, Devalingam
    Halmos, Balazs
    Sirard, Cynthia A.
    Landau, Steven B.
    Ryan, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)
    Ryan, D. P.
    Murphy, J.
    Mahalingam, D.
    Strickler, J.
    Stein, S.
    Sirard, C.
    Landau, S.
    Bendell, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 108 - 108
  • [10] Current results of a phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (P) in patients (pts) with advanced DKK1+esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).
    Ryan, David P.
    Murphy, Janet E.
    Mahalingam, Devalingam
    Halmos, Balazs
    Sirard, Cynthia A.
    Landau, Steven B.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12